Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057
ESMO 2018 CongressRonald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in Bacillus Calmette Geurin–unresponsive bladder cancer with high risk for disease progression.
Related Videos
Matti S. Aapro, MD, on Advanced Disease: Reducing Use of Futile Treatments
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and m...
Alexander M.M. Eggermont, MD, PhD, on Melanoma: Advances in Adjuvant Therapy
Alexander M.M. Eggermont, MD, PhD, of Gustave Roussy, discusses findings from recent adjuvant trials in high-risk melanoma, and what the NCCN Guidelines recommend in light of such data as res...
Matti S. Aapro, MD, on Immunotherapy in Older Patients
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the optimal treatment and supportive care for older patients with cancer, including the importance of maintaining...
Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy
Lisa A. Carey, MD, of the University of North Carolina, and Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, discuss the phase III IMpassion 130 trial t...
Johan F. Vansteenkiste, MD, PhD, on NSCLC: Immunotherapy and Targeted Treatments
Johan F. Vansteenkiste, MD, PhD, of Catholic University Leuven, summarizes a session he co-chaired that included discussion of translating advances in stage IV disease to nonmetast...
